Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence

Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.

More from Archive

More from Medtech Insight